Chargement en cours...
Endogenous Serum IgG Antibodies to Clostridium difficile Toxin B Are Associated with Protection against C. difficile Infection Recurrence
BACKGROUND: MODIFY I/II were global trials of the efficacy and safety of bezlotoxumab (BEZ), a monoclonal antibody (mAb) against C. difficile toxin B, alone and with actoxumab (ACT), a mAb against C. difficile toxin A. BEZ was superior to placebo (PBO) at preventing recurrent CDI (rCDI) in patients...
Enregistré dans:
| Publié dans: | Open Forum Infect Dis |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5631063/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.965 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|